This represents another important step toward making a malaria vaccine more widely available to children most at risk from malaria in sub-Saharan Africa. Read more...
MVI PortfolioWe strategically use our resources to support and advance a range of vaccine approaches that target both humoral and cellular immunity.
Evaluation technology projectsWe partner to develop and optimize new assays and challenge models and support reference and service laboratories.
RTS,SGhana, Kenya, and Malawi to take part in WHO malaria vaccine pilot programme
PATH and GSK welcome progress toward RTS,S malaria vaccine pilot implementation with selection of countries
24 Apr 2017
MVI Welcomes New Support from GHIT Fund for Development of Transmission-Blocking Vaccine
30 Mar 2017
PATH welcomes €7.8 million grant from German government to support testing of malaria vaccine candidate in Africa
1 Dec 2016
PATH and GSK welcome funding from The Global Fund towards malaria vaccine pilot implementation
17 Nov 2016
GSK and PATH welcome results from small early-stage trial that suggests changing the dosing schedule of the candidate malaria vaccine RTS,S may improve its efficacy
6 Sep 2016